Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Tricida Price Performance
Shares of TCDA opened at $13.47 on Friday. The company has a current ratio of 5.11, a quick ratio of 5.11 and a debt-to-equity ratio of 584.92. The company's fifty day simple moving average is $10.44 and its 200 day simple moving average is $9.63. Tricida has a 1-year low of $3.84 and a 1-year high of $13.79. The company has a market cap of $749.86 million, a price-to-earnings ratio of -4.97 and a beta of 0.68.
Wall Street Analysts Forecast Growth
Separately, The Goldman Sachs Group lowered their target price on Tricida from $22.00 to $16.00 and set a "buy" rating on the stock in a research report on Tuesday, May 24th.
Insider Buying and Selling
In other Tricida news, major shareholder Brian M. Isern sold 37,339 shares of Tricida stock in a transaction on Monday, August 15th. The shares were sold at an average price of $13.42, for a total transaction of $501,089.38. Following the completion of the transaction, the insider now directly owns 732,675 shares of the company's stock, valued at $9,832,498.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Tricida news, major shareholder Brian M. Isern sold 37,339 shares of the firm's stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $13.42, for a total transaction of $501,089.38. Following the completion of the sale, the insider now directly owns 732,675 shares in the company, valued at $9,832,498.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Brian M. Isern sold 214,800 shares of the business's stock in a transaction that occurred on Friday, August 12th. The stock was sold at an average price of $13.50, for a total value of $2,899,800.00. Following the sale, the insider now owns 738,276 shares of the company's stock, valued at approximately $9,966,726. The disclosure for this sale can be found here. Over the last 90 days, insiders acquired 999,004 shares of company stock worth $9,517,079. Company insiders own 35.60% of the company's stock.